Renalytix Successfully Transitions to OTCQB Trading
Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a leader in artificial intelligence-driven in vitro diagnostics, has announced its transition to trading on the OTCQB in the United States. This change marks an important step in the company’s strategy to optimize its resources and enhance its focus on kidney health diagnostics.
Reasons for the Shift to OTCQB
After careful consideration, the Directors of Renalytix decided to downlist its American Depository Shares (ADSs) from Nasdaq to the OTCQB. This decision was not taken lightly; it involved evaluating the benefits of maintaining a Nasdaq listing against the associated costs. By moving to OTCQB, Renalytix aims to reduce its general and administrative expenses while still maintaining its importance in the market.
Strategic Focus and Improved Financial Structure
According to James McCullough, CEO of Renalytix, recent financing efforts have strengthened the company’s balance sheet. This financial fortification allows the company to adopt a leaner operational model, ideally positioned to enhance its sales and overall profitability.
McCullough emphasized, “Moving to the OTC market, while retaining our presence on the London Stock Exchange, significantly reduces our costs as a public entity. This enables us to reallocate critical capital resources towards the commercialization of kidneyintelX.” This strategic focus not only aims to enhance shareholder value but also improves the overall patient management experience in kidney disease.
Understanding the OTCQB Venture Market
The OTCQB Venture Market is a premier platform operated by OTC Markets Group Inc. It caters to early-stage U.S. and international companies. To qualify for this market, companies must remain current in their reporting obligations and undergo an annual verification process managed by the OTC Markets Group. This ensures a level of transparency and reliability for investors.
Relevance of OTCQB for Renalytix
Transitioning to OTCQB provides Renalytix with a cost-effective and strategic alternative to Nasdaq. The OTCQB market is recognized by the Securities and Exchange Commission (SEC) as an established public market, facilitating price discovery for companies listing there. This environment may help Renalytix foster growth while engaging effectively with its stakeholders.
About Renalytix plc
With a pioneering role in the realm of bioprognosis for kidney health, Renalytix continues to innovate. The company's kidneyintelX.dkd test has been recognized as the first FDA-authorized prognostic test designed for early-stage chronic kidney disease (CKD) risk assessment in Type 2 diabetes patients. By facilitating earlier interventions, Renalytix aims to improve patient outcomes and reduce healthcare costs significantly.
For further inquiries or information about Renalytix, interested parties can reach out as follows:
Contact Information:
Renalytix plc
James McCullough, CEO
Via Walbrook PR (020 7710 7600)
Stifel Nicolaus Europe Limited (020 7710 7600)
Oberon Capital (020 3179 5300)
Email: renalytix@walbrookpr.com
Email for Investor Relations: investors@renalytix.com
Frequently Asked Questions
What is Renalytix doing on the OTCQB?
Renalytix has transitioned its trading to the OTCQB to reduce costs and improve its operational focus on kidney health diagnostics.
How does OTCQB benefit Renalytix?
The OTCQB allows Renalytix to lower its administrative costs while still providing a recognized platform for trading its securities.
What recent developments have influenced this decision?
Recent financial improvements and a strategic focus on sales growth have encouraged the switch from Nasdaq to the OTCQB.
What is kidneyintelX?
KidneyintelX is a prognostic test developed by Renalytix to assess the risk of chronic kidney disease in Type 2 diabetes patients.
Where can I learn more about Renalytix?
For more information, visit www.renalytix.com.
